Localized Prostate Cancer
Localized Prostate Cancer
Emily MenendezLocalized Prostate Cancer | March 21, 2023
A study arm from the phase 3 EMBARK trial evaluating enzalutamide for nmCSPC with high-risk BCR has had positive outcomes.
Read More
Emily MenendezLocalized Prostate Cancer | March 13, 2023
A recent study analyzed a 15-year follow-up in men with prostate cancer to gauge the effectiveness of different treatments.
Akhil Abraham Saji, MDLocalized Prostate Cancer | February 28, 2023
This review highlights the research on the costs related to the treatment of localized PC and the associated outcomes.
Phouc T. Tran, MD, PhDASCO GU Symposium 2023 | February 24, 2023
Phouc Tran, MD, PhD, highlights the challenges of accurate risk stratification for newly diagnosed localized prostate cancer.
David Nanus, MDASCO GU Symposium 2023 | February 17, 2023
David Nanus, MD, details the ways in which PSMA PET varies in guidelines and is used to stage localized prostate cancer.
Emily MenendezLocalized Prostate Cancer | January 23, 2023
A recent update on the phase 3 MIRAGE trial determined if MRI or CT-guided stereotactic body radiotherapy is most effective.
David Ambinder, MDLocalized Prostate Cancer | January 18, 2023
With a lack of trials that address different surgical options for localized PC, is there evidence to guide patients?
Emily MenendezLocalized Prostate Cancer | January 10, 2023
A recent study investigated the role of FACIT-F as a baseline predictor for OS in patients undergoing SBRT for localized PCa.
Zachary BessetteLocalized Prostate Cancer | December 14, 2022
A prospective study assessed the 4Kscore’s ability to predict prostate cancer tumor progression on active surveillance.
Zachary BessetteLocalized Prostate Cancer | December 5, 2022
18F-sodium fluoride positron emission tomography-computed tomography may better detect skeletal metastases in patients
Leah LawrenceLocalized Prostate Cancer | October 12, 2022
The use of primary whole gland cryoablation had excellent outcomes among men with localized prostate cancer.
David Ambinder, MDJournal | July 27, 2022
Active surveillance and enzalutamide monotherapy for localized prostate cancer is compared with active surveillance alone.
Leah LawrenceLocalized Prostate Cancer | July 21, 2022
The rate of prostate cancer after high-frequency irreversible electroporation ablation was lower than other energy platforms.
GU Oncology Now EditorsLocalized Prostate Cancer | May 20, 2022
The propensity score matching investigated the medical expenditure of RP and IMRT in elderly patients with high-risk LPC.
Vanessa IraAUA 2022 | May 18, 2022
The mental health data comes from one of the largest randomized-controlled trials to date.
Vanessa IraAUA 2022 | May 16, 2022
The therapy represents a valuable strategy in select patients whose disease fails to respond to initial cryoablation or HIFU.
Vanessa IraAUA 2022 | May 16, 2022
The results highlight the need for urologists to consider baseline urinary symptoms in treatment decision-making.